IVI in the Media

EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?

Asia Times | Vaccinations in a race against viral variants

Nature | Why COVID vaccines are so difficult to compare

DEVEX | Opinion: COVAX — too big, and too important, to fail

CNN | “Our response needs to be clear, strong, and unified”

South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think

Bloomberg | Will the Covid-19 Vaccines Be Effective and Safe?

Asian Boss | Update On COVID-19 Vaccine Price & Schedule From A Leading Vaccine Expert

The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19

CGTN | ‘The vaccine itself is not the silver bullet,’ says International Vaccine Institute

Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine

Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea

Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines

Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions

The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line

Devex | Q&A: Is COVID-19 helping or hindering progress toward an HIV vaccine?

TED | The trials, tribulations and timeline of a COVID-19 vaccine

Wired Korea | The End of World War C: Peace without Victory?

Asian Boss | World’s Leading Vaccine Expert Fact-Checks COVID-19 Vaccine Conspiracy

Development Today | Why Sweden funds a vaccine institute in Korea and not Oslo-based CEPI

CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things

The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’

CGTN: The Agenda with Stephen Cole | Speed of vaccine trials is ‘unprecedented’

Asian Boss | We Asked The World’s Leading Vaccine Expert About COVID-19 Vaccine

The Guardian | Test, trace, contain: how South Korea flattened its coronavirus curve

BBC World Service: The Inquiry | How do we come out of the lockdown? (13:00)

ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine

Seeker | How Fast Can We Make a Coronavirus Vaccine?

Education City Speaker Series: Flattening the Curve – Global Responses to COVID-19

Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim

South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute

BBC World News | Jerome Kim: Vaccines are the long-term solution to the pandemic

The Korea Times | Developing vaccine against COVID-19

TRT: Bigger than Five | COVID-19: The World Reacts

South Korea’s fight against coronavirus (CBS News)

NDTV | Top South Korea Doctor On Why He Thinks Coronavirus Is Not A ‘Chinese Virus’

RTE | What South Korea can teach Ireland about fighting Covid-19

Physical distancing should last months, not weeks, says epidemiologist (Yahoo News Canada)

Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)

COVID-19 Pandemic (Arirang TV, 22:50~46:00)

By then, we’ll have a vaccine on our side (Hankyoreh—Korean)

Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)

Testing times: Why South Korea’s COVID-19 strategy is working (Al Jazeera English)

Genexine seeks to compress the vaccine timeline

Genexine, Binex to develop COVID-19 vaccine (Korea Biomedical Review)

Genexine, Binex to co-develop coronavirus vaccine GX-19 (Korea Herald)

How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)

COVID-19 vaccine, drugs on fast track for development: IVI chief (Yonhap News)

Inside the race to find a coronavirus vaccine (Devex)

Chinese students keen for turnaround (China Daily)

China Daily | S. Korea can try out makeshift hospitals, experts say

Director General Jerome Kim for Phoenix TV

Speed and accuracy vital for COVID-19 test kits (Arirang News)

2020 COVID-19 Live Updates: Jerome Kim for tbs eFM

Jerome Kim for KBS WORLD Radio, Korea24 on the COVID-19 outbreak in South Korea

Korea should join efforts in vaccine development to prevent pandemics (JoongAng Ilbo)

Future global health threats

IVI: COVID-19 could linger (Korean)

Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”

Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?

Al Jazeera English | Scientists call for global cooperation over coronavirus

When will COVID-19 vaccine be commercialized…And “super vaccine”? (Korean)

Global push to find vaccine against devastating bug growing

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Korean vaccines expanding global territory

Neglected Victims of Neglected Diseases

Let’s build a common defense against epidemics

Vaccine investment brings 16-fold return… partnering with Bill Gates

World must join forces to prevent infectious diseases

IVI editorial in The Korea Herald advocates for Korean leadership for global health

×

SK Chemicals - IVI Partnership Strengthened to Improve Children’s Health in the Developing World

Author
Margaret
Date
2014-10-30 00:00
Views
3013

 SK Chemicals-IVI Partnership Strengthened

to Improve Children’s Health in the Developing World

 


 

SK Chemicals and the International Vaccine Institute (IVI) vowed to strengthen their existing collaboration as part of efforts to improve the health and wellbeing of poor population in developing countries through continued partnership on vaccine development and delivery.

 

On October 29th, a delegation from IVI that consisted of several of its board members and a delegation from SK Chemicals gathered to review the development status of the typhoid conjugate vaccine and to discuss further collaboration opportunities at the SK Chemicals Headquarters.

 

IVI is a nonprofit international organization that was officially established in 1997 as an initiative of the United Nations Development Programme (UNDP) to prevent and control neglected infectious diseases that afflict the poor, especially children, in developing countries through the discovery, development and delivery of safe, effective, and affordable vaccines. It is the first international organization to have its headquarters based in South Korea. IVI recently announced the appointment of Korean-American scientist, Dr. Jerome H. Kim, as Director General who will start his tenure early next year.

 

 

Having entered into Memorandum of Understanding (MOU) in 2012 between the two organizations, SK Chemicals and IVI signed on Technology Transfer Agreement and Global Access Agreement for the typhoid conjugate vaccine in April 2013 and have initiated the development of the vaccine. SK Chemicals reported that the collaboration product is currently under the preclinical studies and the clinical studies will be initiated next year. After  World Health Organization (WHO) prequalification is achieved for the vaccine, SK Chemicals will produce up to 10 million doses of the product at its Andong Manufacturing Plant in order to supply to the developing world through groups such as Gavi, the Vaccine Alliance and UN International Child Emergency Fund (UNICEF).

 

“IVI is excited to work with SK Chemicals due to their strong commitment to global health. Together, IVI and SK Chemicals will help save lives through the new typhoid conjugate vaccine,” said Mr. John Morahan, Acting Director General of IVI, “We will continue to cooperate closely with SK Chemicals in efforts to improve public health in developing countries through vaccines and vaccination.”

 

Mr. In-Serk Lee, CEO of SK Chemicals expressed his firm will to build a continued collaboration with IVI, stating “The mission of SK Chemicals’ vaccine business is to promote human health. I am glad to see that our mission is being materialized through the development of the typhoid conjugate vaccine in cooperation with IVI.”

 

Typhoid fever is a disease that is caused by the bacterium, Salmonella Typhi, and is spread most commonly by consumption of food or water contaminated with bacteria from human waste. There is almost no occurrence of typhoid fever in industrialized nations but the rate of incidence is still high in developing nations where water systems, hygiene, and infrastructure are still inadequate. According to the WHO, approximately 21 million people contract the disease globally, with over 200,000people dying from it annually.

 

Last August, SK Chemicals received accreditation approval of Good Manufacturing Practice for its Andong Plant, also known as the L HOUSE, from the Korea Ministry of Food and Drug Safety (MFDS), finishing all of the preparation necessary to start commercial vaccine production. Besides the typhoid conjugate vaccine, SK Chemicals has entered into an agreement with Sanofi Pasteur for collaboration in the development and commercialization of a new Pneumococcal vaccine and has established a foundation to enter the global vaccine market.

 

(IVI delegation together with SK Chemicals’ research faculties participating in the development of a typhoid vaccine for children of the developing world.

In-Serk Lee, CEO of SK Chemicals (fifth from left), and John Morahan, Acting Director General of the IVI (fourth from left), shared commitment to improve the health of children in the developing world through continued collaboration between two organizations. )

 

 

 

About IVI

The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int.

 

l  Contacts

Sung-Woo Kim, Team Manager,/SK Chemicals PR Team

Phone: 010-5248-5308

Jun Ho Jung, Manager/SK Chemicals PR Team

Phone: 010-2581-9717

Tae Kyung Byun, Public Awareness/Advocacy Officer, IVI

Phone: +82-2-872-2801 (Ext. 159)     

Mobile: +82-11-9773-6071

Email: tkbyun@ivi.int

DONATE